Case Presentation: A 72 year old man presented with acute onset expressive aphasia. His medical history was notable for hypertension and history of resected colon adenocarcinoma. Neurologic exam was remarkable for expressive aphasia but otherwise normal. Brain MRI was negative for stroke but showed a 0.8cm ring-enhancing, calcified lesion in the left frontal lobe with surrounding edema. Initial CSF, blood and urine studies were unremarkable and negative for neurocysticercosis, histoplasmosis, Cryptococcus, TB, and other bacterial, fungal, mycobacterial, and parasitic infections. Given sudden onset of aphasia and location of frontal mass near Broca’s area, EEG was done and revealed focal status epilepticus arising from the left frontotemporal lobe. He was started on antiepileptic medications and steroid taper for effective seizure control. Given non-invasive testing had failed to reveal a diagnosis, brain biopsy was conducted, which revealed histoplasmosis on histopathologic evaluation. He was started on Liposmal amphothericin B (AMB-L) per Infectious Diesase. Upon further history, it was revealed he had pulmonary histoplasmosis treated with unknown regimen 20 years prior. Baseline creatinine prior to AMB-L was 0.89 mg/dL. Within 1 week of treatment, his creatinine increased to 1.28 mg/dL and peaked at 2.67 mg/dL on day 19. Therefore, AMB-L was discontinued and he was transitioned to voriconazole with subsequent improvement in his creatinine to baseline.
Discussion: CNS involvement occurs in only 5-10% of individuals with disseminated histoplasmosis, most commonly presenting with meningeal symptoms including headache, confusion and/or nuchal rigidity. While most patients with CNS involvement are immunosuppressed, up to one-third are immunocompetent. CNS involvement can be primary CNS infections or manifestations of extrapulmonary histoplasmosis. This case was interesting because we theorize that he had CNS involvement with his initial infection 20 years ago but did not become symptomatic until this presentation for unclear reasons. Alternatively, his presentation could represent a re-activation of latent histoplasmosis or a second infection. Current guidelines recommend treatment with AMB-L for 4-6 weeks, followed by itraconazole for at least 1 year. However, these guidelines are typically for patients who present with fulminant meningitis rather than the mass lesion seen in this case prompting many discussions about optimal treatment strategies for this patient. The nephrotoxic and electrolyte wasting side effects of AMB-L required close monitoring, and development of AKI limited the duration of AMB-L treatment for our patient. We elected to treat with voriconazole as step-down therapy for its superior CNS penetration.
Conclusions: Though rare, disseminated histoplasmosis may manifest with CNS involvement in immunocompetent individuals. The primary CNS infection could remain asymptomatic for many years. While guidelines recommend induction therapy with AMB-L, patients must be closely monitored for renal effects. Voriconazole may be considered for ongoing treatment due to its superior CNS penetration.